288 related articles for article (PubMed ID: 23744553)
1. Oxidative DNA damage in Barrett mucosa: correlation with telomeric dysfunction and p53 mutation.
Cardin R; Piciocchi M; Tieppo C; Maddalo G; Zaninotto G; Mescoli C; Rugge M; Farinati F
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S583-9. PubMed ID: 23744553
[TBL] [Abstract][Full Text] [Related]
2. GERD is associated with shortened telomeres in the squamous epithelium of the distal esophagus.
Souza RF; Lunsford T; Ramirez RD; Zhang X; Lee EL; Shen Y; Owen C; Shay JW; Morales C; Spechler SJ
Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G19-24. PubMed ID: 17395902
[TBL] [Abstract][Full Text] [Related]
3. Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma.
Gertler R; Doll D; Maak M; Feith M; Rosenberg R
Cancer; 2008 May; 112(10):2173-80. PubMed ID: 18348304
[TBL] [Abstract][Full Text] [Related]
4. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
5. Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma.
Cardin R; Piciocchi M; Sinigaglia A; Lavezzo E; Bortolami M; Kotsafti A; Cillo U; Zanus G; Mescoli C; Rugge M; Farinati F
BMC Cancer; 2012 May; 12():177. PubMed ID: 22587342
[TBL] [Abstract][Full Text] [Related]
6. Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis.
Piciocchi M; Cardin R; Cillo U; Vitale A; Cappon A; Mescoli C; Guido M; Rugge M; Burra P; Floreani A; Farinati F
Transl Res; 2016 Feb; 168():122-133. PubMed ID: 26408804
[TBL] [Abstract][Full Text] [Related]
7. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
[TBL] [Abstract][Full Text] [Related]
8. The role of oxidative DNA damage, DNA repair, GSTM1, SOD2 and OGG1 polymorphisms in individual susceptibility to Barrett's esophagus.
Kadioglu E; Sardas S; Ergun M; Unal S; Karakaya AE
Toxicol Ind Health; 2010 Mar; 26(2):67-79. PubMed ID: 20056743
[TBL] [Abstract][Full Text] [Related]
9. Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase.
Vaziri H; Benchimol S
Oncogene; 1999 Dec; 18(53):7676-80. PubMed ID: 10618707
[TBL] [Abstract][Full Text] [Related]
10. Alternative lengthening of telomeres is induced by telomerase inhibitors in Barrett's esophageal cells.
Qin X; Qi B; Zhao B
Oncol Rep; 2013 Apr; 29(4):1399-404. PubMed ID: 23338150
[TBL] [Abstract][Full Text] [Related]
11. Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation.
Carlson N; Lechago J; Richter J; Sampliner RE; Peterson L; Santella RM; Goldblum JR; Falk GW; Ertan A; Younes M
Am J Gastroenterol; 2002 Jun; 97(6):1340-5. PubMed ID: 12094847
[TBL] [Abstract][Full Text] [Related]
12. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
13. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.
Engelhardt M; Drullinsky P; Guillem J; Moore MA
Clin Cancer Res; 1997 Nov; 3(11):1931-41. PubMed ID: 9815582
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus.
Sihvo EI; Ruohtula T; Auvinen MI; Koivistoinen A; Harjula AL; Salo JA
J Thorac Cardiovasc Surg; 2003 Dec; 126(6):1952-7. PubMed ID: 14688711
[TBL] [Abstract][Full Text] [Related]
15. Correlative polymorphism of NAD(P)H: quinone oxidoreductase (NQO1) with telomere shortening in colorectal cancer.
Takagi S; Kinouchi Y; Hiwatashi N; Hirai M; Suzuki S; Takahashi S; Negoro K; Obana N; Shimosegawa T
Anticancer Res; 2002; 22(5):2749-52. PubMed ID: 12529991
[TBL] [Abstract][Full Text] [Related]
16. Control of Cellular Aging, Tissue Function, and Cancer by p53 Downstream of Telomeres.
Roake CM; Artandi SE
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28289249
[TBL] [Abstract][Full Text] [Related]
17. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression.
Farazi PA; Glickman J; Horner J; Depinho RA
Cancer Res; 2006 May; 66(9):4766-73. PubMed ID: 16651430
[TBL] [Abstract][Full Text] [Related]
18. Factors that influence telomeric oxidative base damage and repair by DNA glycosylase OGG1.
Rhee DB; Ghosh A; Lu J; Bohr VA; Liu Y
DNA Repair (Amst); 2011 Jan; 10(1):34-44. PubMed ID: 20951653
[TBL] [Abstract][Full Text] [Related]
19. Replicative senescence of normal human oral keratinocytes is associated with the loss of telomerase activity without shortening of telomeres.
Kang MK; Guo W; Park NH
Cell Growth Differ; 1998 Jan; 9(1):85-95. PubMed ID: 9438392
[TBL] [Abstract][Full Text] [Related]
20. Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer.
Hao XD; Yang Y; Song X; Zhao XK; Wang LD; He JD; Kong QP; Tang NL; Zhang YP
Oncol Rep; 2013 Jan; 29(1):226-36. PubMed ID: 23124483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
